ProKidney [PROK] vs Vertex [VRTX] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: ProKidney wins in 6 metrics, Vertex wins in 11 metrics, with 0 ties. Vertex appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricProKidneyVertexBetter
P/E Ratio (TTM)-4.4228.68ProKidney
Price-to-Book Ratio1.066.02ProKidney
Debt-to-Equity Ratio1.308.89ProKidney
PEG Ratio0.24-0.22Vertex
EV/EBITDA-8.3820.53ProKidney
Profit Margin (TTM)0.00%31.86%Vertex
Operating Margin (TTM)-17,967.87%38.93%Vertex
EBITDA Margin (TTM)N/A38.93%N/A
Return on Equity-40.52%22.77%Vertex
Return on Assets (TTM)-25.30%13.09%Vertex
Free Cash Flow (TTM)$-155.86M$-978.00MProKidney
Dividend Yield305.81%N/AN/A
1-Year Return61.18%-11.42%ProKidney
Price-to-Sales Ratio (TTM)1,552.389.06Vertex
Enterprise Value$1.43B$98.55BVertex
EV/Revenue Ratio2,707.648.63Vertex
Gross Profit Margin (TTM)N/A86.25%N/A
Revenue per Share (TTM)$0$44Vertex
Earnings per Share (Diluted)$-0.56$14.06Vertex
Beta (Stock Volatility)1.780.43Vertex
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

ProKidney vs Vertex Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
ProKidney-1.44%10.04%16.10%328.13%285.92%58.38%
Vertex-1.36%4.55%1.68%-12.25%-16.68%-0.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
ProKidney61.18%-71.04%-72.74%-72.74%-72.74%-72.74%
Vertex-11.42%36.61%49.40%266.64%1,042.17%1,773.20%

News Based Sentiment: ProKidney vs Vertex

ProKidney

News based Sentiment: MIXED

ProKidney experienced significant price fluctuations and conflicting analyst ratings during October 2025. While speculative buying drove up the stock price, insider selling and a downgraded rating from Bank of America create a mixed investment picture. The lack of fundamental news driving these movements adds to the uncertainty.

View ProKidney News Sentiment Analysis

Vertex

News based Sentiment: POSITIVE

Vertex Pharmaceuticals delivered strong financial results in Q2 2025 and raised its full-year guidance, coupled with positive developments in its pipeline and favorable analyst coverage. This combination of factors indicates a positive trajectory for the company and strengthens the investment case.

View Vertex News Sentiment Analysis

Performance & Financial Health Analysis: ProKidney vs Vertex

MetricPROKVRTX
Market Information
Market Cap i$806.33M$103.40B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,296,2801,835,420
90 Day Avg. Volume i1,987,3371,652,450
Last Close$2.74$403.30
52 Week Range$0.46 - $7.13$362.50 - $519.88
% from 52W High-61.57%-22.42%
All-Time High$14.19 (Mar 13, 2023)$519.88 (Nov 04, 2024)
% from All-Time High-80.69%-22.42%
Growth Metrics
Quarterly Revenue Growth-0.04%0.12%
Quarterly Earnings GrowthN/A0.12%
Financial Health
Profit Margin (TTM) i0.00%0.32%
Operating Margin (TTM) i-179.68%0.39%
Return on Equity (TTM) i-0.41%0.23%
Debt to Equity (MRQ) i1.308.89
Cash & Liquidity
Book Value per Share (MRQ)$-7.51$67.02
Cash per Share (MRQ)$2.18$24.90
Operating Cash Flow (TTM) i$-114,420,000$3.85B
Levered Free Cash Flow (TTM) i$-112,575,248$2.91B
Dividends
Last 12-Month Dividend Yield i305.81%N/A
Last 12-Month Dividend i$2.63N/A

Valuation & Enterprise Metrics Analysis: ProKidney vs Vertex

MetricPROKVRTX
Price Ratios
P/E Ratio (TTM) i-4.4228.68
Forward P/E i-5.4521.49
PEG Ratio i0.24-0.22
Price to Sales (TTM) i1,552.389.06
Price to Book (MRQ) i1.066.02
Market Capitalization
Market Capitalization i$806.33M$103.40B
Enterprise Value i$1.43B$98.55B
Enterprise Value Metrics
Enterprise to Revenue i2,707.648.63
Enterprise to EBITDA i-8.3820.53
Risk & Other Metrics
Beta i1.780.43
Book Value per Share (MRQ) i$-7.51$67.02

Financial Statements Comparison: ProKidney vs Vertex

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)PROKVRTX
Revenue/Sales i$230,000$2.96B
Cost of Goods Sold iN/A$407.50M
Gross Profit iN/A$2.56B
Research & Development i$27.26M$978.40M
Operating Income (EBIT) i$-41.39M$1.15B
EBITDA i$-35.76M$1.34B
Pre-Tax Income i$-37.36M$1.28B
Income Tax i$591,000$250.10M
Net Income (Profit) i$-37.95M$1.03B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)PROKVRTX
Cash & Equivalents i$97.81M$4.67B
Total Current Assets i$359.66M$10.01B
Total Current Liabilities i$32.81M$3.78B
Long-Term Debt i$2.51M$1.65B
Total Shareholders Equity i$369.98M$16.50B
Retained Earnings i$-1.22B$10.25B
Property, Plant & Equipment i$3.07M$2.63B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)PROKVRTX
Operating Cash Flow i$-35.14M$404.90M
Capital Expenditures i$-1.14M$-40.70M
Free Cash Flow i$-30.73M$778.20M
Debt Repayment i$-12,000$-1.30M
Common Stock Repurchase iN/A$-696.60M

Short Interest & Institutional Ownership Analysis

MetricPROKVRTX
Shares Short i10.12M4.05M
Short Ratio i4.232.83
Short % of Float i0.11%0.02%
Average Daily Volume (10 Day) i1,296,2801,835,420
Average Daily Volume (90 Day) i1,987,3371,652,450
Shares Outstanding i128.05M256.94M
Float Shares i86.72M255.58M
% Held by Insiders i0.27%0.00%
% Held by Institutions i0.30%0.98%

Dividend Analysis & Yield Comparison: ProKidney vs Vertex

MetricPROKVRTX
Last 12-Month Dividend i$2.63N/A
Last 12-Month Dividend Yield i305.81%N/A
3-Year Avg Annual Dividend i$3.15N/A
3-Year Avg Dividend Yield i36.48%N/A
3-Year Total Dividends i$9.44N/A
Ex-Dividend DateFeb 14, 2025N/A